The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass

Acta Anaesthesiologica Scandinavica

Volumn 44, Issue 3, 2000, Pages 261-273

  Mets, Berend ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Anesthetic agents; Antibiotics; Cardiopulmonary bypass; Muscle relaxants; Opioids; Pharmacokinetics; Volatile anesthetics

Indexed keywords

ALFENTANIL; ANESTHETIC AGENT; ANTIBIOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CEFAZOLIN; DIMETHYLTUBOCURARINE CHLORIDE; ENFLURANE; ETOMIDATE; FENTANYL; HALOTHANE; HEPARIN; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT; ISOFLURANE; KETAMINE; LIDOCAINE; LORAZEPAM; METHOHEXITAL; MIDAZOLAM; MUSCLE RELAXANT AGENT; OPIATE DERIVATIVE; PANCURONIUM; PROPOFOL; PROPRANOLOL; PROTAMINE; REMIFENTANIL; SUFENTANIL; THIOPENTAL; UNINDEXED DRUG; VERAPAMIL;

BLOOD FLOW; CARDIOPULMONARY BYPASS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RESEARCH; DRUG SOLUBILITY; HEMODILUTION; HUMAN; HYPOTENSION; HYPOTHERMIA; LUNG; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW;

ANALGESICS, OPIOID; ANESTHETICS; ANTI-BACTERIAL AGENTS; BLOOD PROTEINS; CARDIOPULMONARY BYPASS; CARDIOVASCULAR AGENTS; HEMODILUTION; HUMANS; MUSCLE RELAXANTS, CENTRAL; PROTEIN BINDING;

EID: 0034099021     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-6576.2000.440308.x     Document Type: Review

References (106)

1. Mets B. Cardiac Pharmacology. In: Thys D, ed. Text Book of Cardiothoracic Anesthesiology. New York: McGraw-Hill, 2000: Chapter 15.
2. Kamath B, Thomson D, Jonston B. Administration of drugs during a cardiopulmonary bypass. Anaesthesia 1980: 35: 908-913.
3. Rosen D, Rosen K. Elimination of drugs and toxins during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997: 11: 337-340.
4. Buylaert W, Herregods L, Mortier E, Bogaert M. Cardiopulmonary bypass and the pharmacokinetics of drugs. Clin Pharmacokinet 1989: 17: 10-26.
5. Wood M. Plasma drug binding: implications for anesthesiologists. Anesth Analg 1986: 65: 786-804.
6. Kumar K, Crankshaw D, Morgan D. The effect of cardiopulmonary bypass on plasma binding of alfentanil. Eur J Clin Pharmacol 1988: 35: 47-52.
7. Bjorksten A, Crankshaw D, Morgan D. The effects of cardiopulmonary bypass on plasma concentrations and protein binding of methohexital and thiopental. J Caridothorac Anesth 1988: 2: 281-289.
8. Wood M, Shand D, Wood A. Propranolol binding in plasma during cardiopulmonary bypass. Anesthesiology 1979: 51: 512-516.
9. Morrell D, Harrison G. Lignocaine kinetics during cardiopulmonary bypass. Br J Anaesth 1983: 55: 1173-1177.
10. Mori A, Watanabe K, Onoe M, Watarida S, Nakamura Y, Tatsho M et al. Regional blood flow in the liver, pancreas and kidney during pulsatile and nonpulsatile perfusion under profound hypothermia. Japanese Circulation Journal 1988: 52: 219-227.
11. Mathie R. Hepatic blood flow during cardiopulmonary bypass. Crit Care Med 1993: 21: S72-S76.
12. Stenson R, Constantino R, Harrison D. Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. Circulation 1971: 63: 205-211.
13. Wilkinson G. Pharmacokinetics of drug disposition: Hemodynamic considerations. Ann Rev Pharmacol 1975: 15: 11-27.
14. Stanley T. Arterial pressure and deltoid muscle gas tensions during cardiopulmonary bypass in man. Can Anaesth Soc J 1978: 25: 286-290.
15. McAllister RG, Jr., Tan TG. Effect of hypothermia on drug metabolism. In vitro studies with propranolol and verapamil. Pharmacology 1980: 20: 95-100.
16. Larsen J. The effects of cooling on liver function in cats. Acta Physiol Scand 1971: 81: 197-207.
17. Holley F, Ponganis K, Stanski D. Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clin Pharmacokinet 1982: 7: 234-251.
18. Puig M, Warner W, Tang C. Effects of temperature on the interaction of morphine with opioid receptors. Br J Anaesth 1987: 59: 1459-1464.
19. Antognini J. Hypothermia eliminates isoflurane requirements at 20 degrees celsius. Anesthesiology 1993: 78: 1152-1156.
20. Roth R, Wiersma D. Role of the lung in total body clearance of circulating drugs. Clin Pharmacokinet 1979: 4: 355-367.
21. Hall R. The pharmacokinetic behavior of opioids administered during cardiac surgery. Can J Anaesth 1991: 38: 747-756.
22. Bentley J, Conahan T, Cork R. Fentanyl sequestration in lungs during cardiopulmonary bypass. Clin Pharmacol Ther 1983: 34: 703-706.
23. Okutani R, Philbin D, Rosow C. Effect of hypothermic hemodilutional cardiopulmonary bypass on plasma sufentanil and catecholamine concentrations in humans. Anesth Analg 1988: 67: 667-670.
24. Koren G, Crean P, Klein J, Goresky G, Villamater J, MacLeod S. Sequestration of fentanyl by the cardiopulmonary bypass (CPBP). Eur J Clin Pharmacol 1984: 27: 51-56.
25. Skacel M, Knott C, Reynolds F, Aps C. Extracorporeal circuit sequestration of fentanyl and alfentanil. Br J Anaesth 1986: 58: 947-949.
26. Rosen D, Rosen K, Davidson B. Fentanyl uptake by the scimed membrane oxygenator. J Caridothorac Anesth 1988: 2: 619-626.
27. Hynynen M. Binding of fentanyl and alfentanil to the extracorporeal circuit. Acta Anaesthesiol Scand 1987: 31: 706-710.
28. Durkan W, Lonergan M, Schwartz S. Effect of membrane oxygenators on sufentanil blood levels during cardiopulmonary bypass. Anesth Analg 1988: 67: S54.
29. Stone J, Damask M, Khambatta H. Is sufentanil removed by blood conservation devices? J Caridothorac Anesth 1988: 2: 615-618.
30. O'Rullian JJ, Wise RK, McCoach RM, Kingsley CP, Williams DR. The effects of haemofiltration on cefazolin levels during cardiopulmonary bypass [In Process Citation]. Perfusion 1998: 13: 176-180.
31. Mets B, Rose-Innes C, Lotz Z, Hickman R, Chalton D. Comparison of in vivo and ex vivo porcine liver function using the same liver. J Hepatol 1993: 17: 3-9.
32. Massey NA, Sherry K, Oldroyd S, Peacock J. Pharmacokinetics of an infusion of propofol during cardiac surgery. Br J Anaesth 1990: 65: 475-479.
33. Dawson PJ, Bjorksten AR, Blake DW, Goldblatt JC. The effects of cardiopulmonary bypass on total and unbound plasma concentrations of propofol and midazolam. J Cardiothorac Vasc Anesth 1997: 11: 556-561.
34. Bailey JM, Mora CT, Shafer SL. Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. Anesthesiology 1996: 84: 1288-1297.
35. Russell G, Wright E, Fox M, Douglas E, Cockshott I. Propofol-fentanyl anaesthesia for coronary artery surgery and cardiopulmonary bypass. Anaesthesia 1989: 44: 205-208.
36. Hammaren E, Yli-Hankala A, Rosenberg PH, Hynynen M. Cardiopulmonary bypass-induced changes in plasma concentrations of propofol and in auditory evoked potentials. Br J Anaesth 1996: 77: 360-364.
37. Lee H, Khoo Y, Chua B, Ng A, Tan S, Chew S. Pharmacokinetics of propofol infusion in asian patients undergoing coronary artery bypass grafting. Ther Drug Monit 1995: 17: 336-341.
38. Hynynen M, Hammaren E, Rosenberg PH. Propofol sequestration within the extracorporeal circuit. Can J Anaesth 1994: 41: 583-588.
39. Hammaren E, Rosenberg P, Hynynen M. Coating of extracorporeal circuit with heparin does not prevent sequestration of propofol in vitro. Br J Anaesth 1999: 82: 38-40.
40. Gepts E, Camu F, Cockshott I, Douglas E. Disposition of profolol administered as constant rate intravenous infusion in humans. Anesth Analg 1987: 66: 1256-1263.
41. Oduro A, Tomlinson A, Voice A, Davies G. The use of etomidate infusions during anaesthesia for cardiopulmonary bypass. Anaesthesia 1983: 38S: 273-308.
42. Morgan D, Crankshaw D, Prideaux P, Chan H, Boyd M. Thiopentone levels during cardiopulmonary bypass. Anaesthesia 1986: 41: 4-10.
43. Hynynen M, Olkkola T, Naveri E, Palojoki R, Neuvonen P, Heinonen J. Thiopentone pharmacokinetics during cardiopulmonary bypass with a nonpulsatile. Acta Anaesthesiol Scand 1989: 33: 554-560.
44. Lehot JJ, Boulieu R, Foussadier A, George M, Clerc J, Villard J et al. Comparison of the pharmacokinetics of methohexital during cardiac surgery with cardiopulmonary bypass and vascular surgery. J Cardiothorac Vasc Anesth 1993: 7: 30-54.
45. McLean R, Baker A, Walker S, Mazer C, Wong B, Harrington E. Ketamine concentrations during cardiopulmonary bypass. Can J Anaesth 1996: 43: 580-584.
46. Hughes M, Glass PA, Jacobs J. Context sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992: 76: 334-341.
47. Kapila A, Glass P, Jacobs J, Muir K, Hermann D, Shiraishi M et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology 1995: 83: 968-975.
48. Nussmeier N, Lambert M, Moskowitz G, Eger E. Washin and washout of three volatile anesthetics concurrently administered during cardiopulmonary bypass. Anesthesiology 1988: 69: A84-A89.
49. Nussmeier N, Moskowitz G, Weiskopf R, Cohen N, Fisher D, Eger E. In vitro anesthetic washin and washout via bubble oxygenators. Anesth Analg 1988: 67: 982-987.
50. Nussmeier N, Lambert M, Moskowitz G, Cohen N, Weiskopf R, Fisher D et al. Washin and washout of isoflurane adminstered via bubble oxygenators during hypothermic cardiopulmonary bypass. Anesthesiology 1989: 71: 519-525.
51. Stern R, Weiss C, Steinbach J, Evers A. Isoflurane uptake and elimination are delayed by absorption of anesthetic by the scimed membrane oxygenator. Anesth Analg 1989: 69: 657-662.
52. Boscoe M, Dawling S, Thompson M, Jones R. Lorazepam in open-heart surgery - plasma concentrations before, during and after bypass following different dose regimens. Anaesth Intensive Care 1984: 12: 9-13.
53. Aaltonen L, Kanto J, Arola M, Iisalo E, Pakkanen A. Effect of age and cardiopulmonary bypass on the pharmacokinetics of lorazepam. Acta Pharmacol Toxicol 1982: 51: 126-131.
54. Desmond P, Roberts R, Wood A, Dunn G. Wilkinson G, Schenker S. Effect of heparin administration on plasma binding of benzodiazepines. Br J Clin Pharmacol 1980: 9: 171-175.
55. Rosen D, Rosen K, Leong P. Uptake of lorazepam and midazolam by the scimed membrane oxygenator. Anesthesiology 1990: 73: A474.
56. Kanto J, Himberg J, Heikkila H, Arola M, Jalonen J, Laasonen V. Midazolam kinetics before, during and after cardiopulmonary bypass surgery. Int J Clin Pharmacol Res 1985: 2: 123-126.
57. Maitre P, Funk B, Crevoisier C, Ha H. Pharmacokinetics of midazolam in patients recovering from cardiac surgery. Eur J Clin Pharmacol 1989: 37: 161-166.
58. Mathews H, Carson I, Lyons S, Orr I, Collier P, Howard P et al. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br J Anaesth 1988: 61: 302-307.
59. Bailey P, Stanley T. Narcotic intravenous anesthetics. In: Miller R, ed. Anesthesia. vol 1, 3rd edn. New York. Churchill Livingstone: 1990, 281: 366.
60. Bovill J, Sebel P. Pharmacokinetics of high-dose fentanyl. A study in patients undergoing cardiac surgery. Br J Anaesth 1980: 52: 795-801.
61. Flezzani P, Alvis J, Jacobs J. Sufentanil disposition during cardiopulmonary bypass. Can J Anaesth 1987: 34: 566-569.
62. Hug C, Burm A, deLange S. Alfentanil pharmacokinetics in cardiac surgical patients. Anesth Analg 1993: 78: 231-239.
63. Koska A, Romagnoli A, Kramer W. Effect of cardiopulmonary bypass on fentanyl distribution and elimination. Clin Pharmacol Ther 1981: 29: 100-105.
64. Futter M, Whalley D, Wynands J, Bevan D. Pancuronium requirements during hypothermic cardiopulmonary bypass in man. Anaesth Intensive Care 1983: 11: 216-219.
65. d'Hollander A, Duvaldestin P, Henzel D, Nevelsteen M, Bomblet J. Variations in pancuronium requirement, plasma concentration, and urinary excretion induced by cardiopulmonary. Anesthesiology 1983: 58: 505-509.
66. Walker J, Brown K. Alcuronium kinetics in patients undergoing cardiopulmonary bypass sugery. Br J Clin Pharmacol 1983: 15: 237-244.
67. Walker J, Shanks C, Brown K. Altered d-tubocurarine disposition during cardiopulmonary bypass surgery. Clin Pharmacol Ther 1984: 35: 686-694.
68. Avram M, Shanks C, Henthorn T, Ronai A, Kinzer J, Wilkinson C. Metrocurine kinetics in patients undergoing operations requiring cardiopulmonary bypass. Clin Pharmacol Ther 1987: 42: 576-581.
69. Hudson ME, Rothfield KP, Tullock WC, Firestone LL. Haemodynamic effects of rocuronium bromide in adult cardiac surgical patients. Can J Anaesth 1998: 45: 139-143.
70. Smeulers NJ, Wierda JM, van den Broek L, Gallandat Huet RC, Hennis PJ. Effects of hypothermie cardiopulmonary bypass on the pharmacodynamics and pharmacokinetics of rocuronium. J Cardiothorac Vasc Anesth 1995: 9: 700-705.
71. Flynn P, Hughes R, Walton B. Use of atracurium in cardiac surgey involving cardiopulmonary bypass with induced hypothermia. Br J Anaesth 1984: 56: 967-972.
72. Ham J, Stanski D, Newfield P, Miller R. Pharmacokinetics and dynamics of d-tubocurarine during hypothermia in humans. Anesthesiology 1981: 55: 631-635.
73. Buzello W, Schluermann D, Schindler M, Spillner G. Hypothermic cardiopulmonary bypass and neuromuscular blockade by pancuronium and vecuronium. Anesthesiology 1985: 62: 201-204.
74. Agoston A, Vandenbrom R, Mark J, Wierda K. Clinical pharmacokinetics of neuromuscular blocking drugs. Clin Pharmacokinet 1992: 22: 94-115.
75. Miller K, McCoy H, Chan K, Fischer R, Lindsay W, Seifert R et al. Effect of cardiopulmonary bypass on cefazolin disposition. Clin Pharmacol Ther 1980: 27: 550-556.
76. Miller K, Can K, McCoy H, Fischer R, Lindsay W, Zaske D. Cephalothin kinetics: before, during, and after cardiopulmonary bypass surgery. Clin Pharmacol Ther 1979: 26: 54-62.
77. Polk R, Archer G, Lower R. Cefamandole kinetics during cardiopulmonary bypass. Clin Pharmacol Ther 1978: 23: 473-480.
78. Lehot JJ, Reverdy ME, Etienne J, Corot C, Nervi C, Sear J et al. Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. J Cardiothorac Anesth 1990: 4: 204-209.
79. Klamerus K, Rodvold K, Silverman N, Levitsky S. Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition. Antimicrob Agents Chemother 1988: 32: 631-635.
80. Cohen P, Collart L, Prober CG, Fischer AF, Blaschke TF. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr Infect Dis J 1990: 9: 562-566.
81. Munzenberger PJ, Massoud N. Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans 1991: 37: 16-18.
82. Moller J, Gilman J, Kearns G, Sussmane J, Raszynski A, Wolfsdorf J et al. Effect of extracorporeal membrane oxygenation on tobramycin pharmacokinetics in sheep. Crit Care Med 1992: 20: 1454-1458.
83. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 1993: 15: 263-266.
84. Lell W, Johnson P, Plagenhoef J, Samuelson P, Athanasuleas C, Hughes W et al. The effect of prophylactic nitroglycerin infusion on the incidence of regional wall-motion abnormalities and ST segment changes in patients undergoing coronary artery bypass surgery. J Card Surg 1993: 8: 228-231.
85. Booth B, Henderson M, Milne B, Cervenko F, Marks G, Brien J et al. Sequestration of glyceryl trinitrate (nitroglycerin) by cardiopulmonary bypass oxygenators. Anesth Analg 1991: 72: 493-497.
86. Dasta J, Jacobi J, Shu L, Sokoloski T, Beckley P, Reilly T et al. Loss of nitroglycerin to cardiopulmonary bypass apparatus. Crit Care Med 1983: 11: 50-52.
87. Dasta J, Weber R, Shu L, Sokoloski T, Kakos G, Smith D et al. Influence of cardiopulmonary bypass on nitroglycerin clearance. J Clin Pharmacol 1986: 26: 165-168.
88. Landow L, Wilson J, Heard SO, Townsend P, Van der Salm TJ, Okike ON et al. Free and total lidocaine levels in cardiac surgical patients. J Cardiothorac Anesth 1990: 4: 340-347.
89. Davies R, Dube L, Mousseau N, McGilveray I, Beanlands D. Perioperative variability of binding of lidocaine, quinidine, and propranolol after cardiac operations. J Thorac Cardiovasc Surg 1988: 96: 634-541.
90. Holley F, Ponganis K, Stanski D. Effects of cardiac surgery with cardiopulmonary bypass on lidocaine disposition. Clin Pharmacol Ther 1984: 35: 617-626.
91. Bailey JM, Levy JH, Rogers HG, Szlam F, Hug CC Jr. Pharmacokinetics of amrinone during cardiac surgery. Anesthesiology 1991: 75: 961-968.
92. Bailey JM, Levy JH, Kikura M, Szlam F, Hug CC, Jr. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anesthesiology 1994: 81: 616-622.
93. Das PA, Skoyles JR, Sherry KM, Peacock JE, Fox PA, Woolfrey SG. Disposition of milrinone in patients after cardiac surgery. Br J Anaesth 1994: 72: 426-429.
94. Butterworth J, Hines R, Royster R, James R. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. Anesth Analg 1995: 81: 783-792.
95. McAllister RG, Jr., Bourne DW, Tan TG, Erickson JL, Wachtel CC, Todd EP. Effects of hypothermia on propranolol kinetics. Clin Pharmacol Ther 1979: 25: 1-7.
96. Plachetka JR, Salomon NW, Copeland JG. Plasma propranolol before, during, and after cardiopulmonary bypass. Clin Pharmacol Ther 1981: 30: 745-751.
97. Giacomini K, Swezey S, Giacomini J, Blaschke T. Administration of heparin causes in vitro release of non-esterified fatty acids in human plasma. Life Sci 1980: 27: 771-780.
98. Katz R, Kanchuger M, Patton K, Eide T. Effect of cardiopulmonary bypass on plasma levels of nifedipine. Anesth Analg 1990: 71: 411-414.
99. Finegan BA, Hussain MD, Tam YK. Pharmacokinetics of diltiazem in patients undergoing coronary artery bypass grafting. Ther Drug Monit 1992: 14: 485-492.
100. Boulieu R, Bonnefous JL, Leho JJ, Durand PG, Chassignolle JF, Ferry S. Effect of cardiopulmonary bypass on plasma concentrations of diltiazem and its two active metabolites. J Pharm Pharmacol 1994: 46: 310-312.
101. Holley F, Ponganis K, Stanski D. Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clin Pharmacokinet 1982: 7: 234-251.
102. Morrison J, Killip T. Serum digitalis and arrhythmia in patients undergoing cardiopulmony bypass. Circulation 1973: 47: 341-352.
103. Coltart D, Chamberlain D, Howard M, Kettlewell M, Mercer J, Smith T. Effect of cardiopulomary bypass on plasma digoxin concentrations. Br Heart J 1971: 33: 334-338.
104. Mooradian A. Digitalis: an update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clin Pharmacokinet 1988: 15: 165-179.
105. Holley F, Ponganis K, Stanski D. Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clin Pharmacokinet 1982: 7: 234-351.
106. Mets B, Hickman R, Allin R, Dyk JV, Lotz Z. Effect of hypoxia on the hepatic metabolism of lidocaine in the isolated perfused pig liver. Hepatology 1993: 19: 668-676.